|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MT1M |
Gene summary for MT1M |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MT1M | Gene ID | 4499 |
| Gene name | metallothionein 1M | |
| Gene Alias | MT-1M | |
| Cytomap | 16q13 | |
| Gene Type | protein-coding | GO ID | GO:0006873 | UniProtAcc | A0A024R6T4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 4499 | MT1M | C09 | Human | Oral cavity | OSCC | 1.38e-10 | -5.20e-01 | 0.1431 |
| 4499 | MT1M | EOLP-1 | Human | Oral cavity | EOLP | 1.59e-18 | -7.70e-01 | -0.0202 |
| 4499 | MT1M | EOLP-2 | Human | Oral cavity | EOLP | 1.61e-14 | -6.57e-01 | -0.0203 |
| 4499 | MT1M | NEOLP-1 | Human | Oral cavity | NEOLP | 6.91e-05 | -2.26e-01 | -0.0194 |
| 4499 | MT1M | NEOLP-2 | Human | Oral cavity | NEOLP | 3.37e-08 | -9.97e-02 | -0.0196 |
| 4499 | MT1M | NEOLP-3 | Human | Oral cavity | NEOLP | 6.89e-07 | -5.24e-02 | -0.0191 |
| 4499 | MT1M | SYSMH1 | Human | Oral cavity | OSCC | 8.16e-25 | -9.03e-01 | 0.1127 |
| 4499 | MT1M | SYSMH4 | Human | Oral cavity | OSCC | 8.15e-17 | -7.92e-01 | 0.1226 |
| 4499 | MT1M | SYSMH5 | Human | Oral cavity | OSCC | 8.67e-19 | -8.54e-01 | 0.0647 |
| 4499 | MT1M | SYSMH6 | Human | Oral cavity | OSCC | 2.73e-10 | -6.09e-01 | 0.1275 |
| 4499 | MT1M | GSM5252126_BPH283PrGF_Via | Human | Prostate | BPH | 2.07e-06 | 5.37e-01 | -0.1771 |
| 4499 | MT1M | GSM5252129_BPH327PrSF_Via | Human | Prostate | BPH | 1.62e-02 | 1.37e+00 | -0.1697 |
| 4499 | MT1M | GSM5252130_BPH340PrGF_Via | Human | Prostate | BPH | 9.04e-03 | 3.14e-01 | -0.1972 |
| 4499 | MT1M | GSM5252134_BPH511PrG_Fcol_3GEX | Human | Prostate | BPH | 2.00e-09 | 7.05e-01 | -0.1433 |
| 4499 | MT1M | GSM5252136_BPH556PrGA1_Fcol | Human | Prostate | BPH | 5.37e-18 | 5.36e-01 | -0.23 |
| 4499 | MT1M | GSM5252137_BPH556PrGA2_Fcol | Human | Prostate | BPH | 2.97e-16 | 6.38e-01 | -0.23 |
| 4499 | MT1M | 047563_1562-all-cells | Human | Prostate | BPH | 3.91e-05 | 3.51e-01 | 0.0791 |
| 4499 | MT1M | 048752_1579-all-cells | Human | Prostate | BPH | 3.28e-10 | 3.31e-01 | 0.1008 |
| 4499 | MT1M | Dong_P3 | Human | Prostate | Tumor | 7.14e-21 | 3.62e-01 | 0.0278 |
| 4499 | MT1M | Dong_P5 | Human | Prostate | Tumor | 6.45e-03 | 6.70e-02 | 0.053 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0009636 | Colorectum | AD | response to toxic substance | 88/3918 | 262/18723 | 1.12e-06 | 3.72e-05 | 88 |
| GO:0055076 | Colorectum | AD | transition metal ion homeostasis | 53/3918 | 138/18723 | 1.89e-06 | 5.65e-05 | 53 |
| GO:0046916 | Colorectum | AD | cellular transition metal ion homeostasis | 43/3918 | 115/18723 | 3.62e-05 | 6.56e-04 | 43 |
| GO:0098754 | Colorectum | AD | detoxification | 53/3918 | 152/18723 | 4.63e-05 | 7.98e-04 | 53 |
| GO:0046686 | Colorectum | AD | response to cadmium ion | 27/3918 | 68/18723 | 3.19e-04 | 3.80e-03 | 27 |
| GO:0010038 | Colorectum | AD | response to metal ion | 106/3918 | 373/18723 | 3.22e-04 | 3.83e-03 | 106 |
| GO:0055069 | Colorectum | AD | zinc ion homeostasis | 18/3918 | 40/18723 | 5.36e-04 | 5.74e-03 | 18 |
| GO:0071276 | Colorectum | AD | cellular response to cadmium ion | 18/3918 | 40/18723 | 5.36e-04 | 5.74e-03 | 18 |
| GO:0071248 | Colorectum | AD | cellular response to metal ion | 61/3918 | 197/18723 | 5.74e-04 | 6.09e-03 | 61 |
| GO:0071241 | Colorectum | AD | cellular response to inorganic substance | 68/3918 | 226/18723 | 6.98e-04 | 7.10e-03 | 68 |
| GO:0006882 | Colorectum | AD | cellular zinc ion homeostasis | 17/3918 | 38/18723 | 8.26e-04 | 8.13e-03 | 17 |
| GO:0097501 | Colorectum | AD | stress response to metal ion | 10/3918 | 19/18723 | 2.25e-03 | 1.77e-02 | 10 |
| GO:0045926 | Colorectum | AD | negative regulation of growth | 70/3918 | 249/18723 | 4.07e-03 | 2.83e-02 | 70 |
| GO:0071294 | Colorectum | AD | cellular response to zinc ion | 11/3918 | 24/18723 | 5.43e-03 | 3.55e-02 | 11 |
| GO:0010273 | Colorectum | AD | detoxification of copper ion | 8/3918 | 15/18723 | 5.67e-03 | 3.64e-02 | 8 |
| GO:1990169 | Colorectum | AD | stress response to copper ion | 8/3918 | 15/18723 | 5.67e-03 | 3.64e-02 | 8 |
| GO:0071280 | Colorectum | AD | cellular response to copper ion | 12/3918 | 28/18723 | 7.21e-03 | 4.39e-02 | 12 |
| GO:0046688 | Colorectum | AD | response to copper ion | 16/3918 | 42/18723 | 8.10e-03 | 4.76e-02 | 16 |
| GO:00096361 | Colorectum | SER | response to toxic substance | 71/2897 | 262/18723 | 8.63e-07 | 4.07e-05 | 71 |
| GO:00987541 | Colorectum | SER | detoxification | 46/2897 | 152/18723 | 3.02e-06 | 1.20e-04 | 46 |
| Page: 1 2 3 4 5 6 7 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0497814 | Prostate | BPH | Mineral absorption | 20/1718 | 60/8465 | 1.22e-02 | 3.61e-02 | 2.23e-02 | 20 |
| hsa0497815 | Prostate | BPH | Mineral absorption | 20/1718 | 60/8465 | 1.22e-02 | 3.61e-02 | 2.23e-02 | 20 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MT1M | SNV | Missense_Mutation | c.4N>A | p.Asp2Asn | p.D2N | Q8N339 | protein_coding | deleterious_low_confidence(0.02) | possibly_damaging(0.831) | TCGA-E9-A1ND-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | aromasin | SD | |
| MT1M | insertion | Nonsense_Mutation | novel | c.83_84insAGACATTTGAGTCTTCAGGGTTCAGCACAGAAGGTT | p.Ser28_Cys29insAspIleTerValPheArgValGlnHisArgArgPhe | p.S28_C29insDI*VFRVQHRRF | Q8N339 | protein_coding | TCGA-A8-A0AD-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| MT1M | SNV | Missense_Mutation | rs568220625 | c.49N>A | p.Gly17Ser | p.G17S | Q8N339 | protein_coding | tolerated(0.37) | benign(0.009) | TCGA-AA-3949-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| MT1M | SNV | Missense_Mutation | c.88N>G | p.Lys30Glu | p.K30E | Q8N339 | protein_coding | deleterious(0.01) | benign(0.225) | TCGA-D5-6928-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| MT1M | SNV | Missense_Mutation | c.80N>A | p.Thr27Asn | p.T27N | Q8N339 | protein_coding | deleterious(0) | possibly_damaging(0.508) | TCGA-DC-4749-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| MT1M | SNV | Missense_Mutation | novel | c.179N>A | p.Cys60Tyr | p.C60Y | Q8N339 | protein_coding | deleterious_low_confidence(0.02) | probably_damaging(0.998) | TCGA-AX-A2HA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| MT1M | SNV | Missense_Mutation | c.177C>G | p.Cys59Trp | p.C59W | Q8N339 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.998) | TCGA-BG-A0M4-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | SD | |
| MT1M | SNV | Missense_Mutation | novel | c.38G>A | p.Cys13Tyr | p.C13Y | Q8N339 | protein_coding | deleterious(0.02) | probably_damaging(0.958) | TCGA-73-A9RS-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Chemotherapy | carboplatin | PD |
| MT1M | SNV | Missense_Mutation | c.85T>A | p.Cys29Ser | p.C29S | Q8N339 | protein_coding | deleterious(0.01) | probably_damaging(0.995) | TCGA-CD-8531-01 | Stomach | stomach adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | epirubicin | CR |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |